UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): 

March 1, 2019 

GILEAD SCIENCES, INC. 

(Exact name of registrant as specified in its charter) 

 [DATA_TABLE_REMOVED]  

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

 (Address of principal executive offices)

94404

 (Zip Code) 

(650) 574-3000

 (Registrant’s telephone number, including area code) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company o 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 

Section 5 - CORPORATE GOVERNANCE AND MANAGEMENT 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers  

As of March 1, 2019, Daniel O’Day was appointed by the Gilead Sciences, Inc. Board of Directors (“Board”) as a member of the Board and as Chief Executive Officer and Chairman of the Board. As previously announced, on the same date, John C. Martin, Ph.D. resigned from the Board. 

2 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

      GILEAD SCIENCES, INC.   

      (Registrant)   

      /s/ Brett A. Pletcher   

      Brett A. Pletcher   

      EVP, General Counsel and Corporate Secretary    

Date: March 1, 2019 

3